Purple biotech completes patient enrollment in phase 2 pancreatic cancer trial

This acceleration of recruitment is expected to result in earlier look at overall survival of patients rehovot, israel, dec. 14, 2023 (globe newswire) --  purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has completed patient enrollment in a phase 2 study of cm24, a multi-functional immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (pdac).
PPBT Ratings Summary
PPBT Quant Ranking